HLB Therapeutics Co (XKRX:115450) FCF Margin % : 58.01% (As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. HLB Therapeutics Co's Free Cash Flow for the three months ended in Dec. 2023 was ₩9,091 Mil. HLB Therapeutics Co's Revenue for the three months ended in Dec. 2023 was ₩15,671 Mil. Therefore, HLB Therapeutics Co's FCF Margin % for the quarter that ended in Dec. 2023 was 58.01%.

As of today, HLB Therapeutics Co's current FCF Yield % is -0.34%.

The historical rank and industry rank for HLB Therapeutics Co's FCF Margin % or its related term are showing as below:

XKRX:115450' s FCF Margin % Range Over the Past 10 Years
Min: -114.9 Med: -34.49 Max: -4.31
Current: -4.31

During the past 13 years, the highest FCF Margin % of HLB Therapeutics Co was -4.31%. The lowest was -114.90%. And the median was -34.49%.

XKRX:115450's FCF Margin % is ranked better than
76.37% of 1041 companies
in the Biotechnology industry
Industry Median: -141.21 vs XKRX:115450: -4.31

HLB Therapeutics Co FCF Margin % Historical Data

The historical data trend for HLB Therapeutics Co's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co FCF Margin % Chart

HLB Therapeutics Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-27.60

-45.94

-34.88

-33.95

-4.53

HLB Therapeutics Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-135.30	98.60	-193.87	-39.75	58.01

Competitive Comparison of HLB Therapeutics Co's FCF Margin %

For the Biotechnology subindustry, HLB Therapeutics Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLB Therapeutics Co's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's FCF Margin % distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's FCF Margin % falls into.

HLB Therapeutics Co FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

HLB Therapeutics Co's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-2432.715	/	53749.063
	=	-4.53 %

HLB Therapeutics Co's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	9090.943	/	15670.9
	=	58.01 %

HLB Therapeutics Co FCF Margin % Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

HLB Therapeutics Co (XKRX:115450) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811

Website

https://www.hlbtherapeutics.co.kr

HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines